Skip to content

Advertisement

You're viewing the new version of our site. Please leave us feedback.

Learn more

BMC Gastroenterology

Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Factors associated with growth disturbance at celiac disease diagnosis in children: A retrospective cohort study

  • Samuli Nurminen1, 2,
  • Laura Kivelä1, 2,
  • Juha Taavela2,
  • Heini Huhtala3,
  • Markku Mäki2,
  • Katri Kaukinen1, 4 and
  • Kalle Kurppa1, 2Email author
BMC Gastroenterology201515:125

https://doi.org/10.1186/s12876-015-0357-4

Received: 18 June 2015

Accepted: 25 September 2015

Published: 6 October 2015

Abstract

Background

Impaired growth is a well-known complication in celiac disease, but factors associated with it are poorly known. We investigated this issue in a large cohort of children.

Methods

530 children with biopsy-proven celiac disease were included. The participants were divided into two groups on the basis of the presence (n = 182) or absence (n = 348) of growth disturbance at diagnosis. Histological, serological and clinical characteristics were compared between children with growth failure and those with normal growth. Further, patients with growth failure as the sole clinical presentation were compared to those with poor growth and concomitant other symptoms.

Results

Children with growth failure were younger (p < 0.001) and had lower hemoglobin (p = 0.016) and higher celiac antibody (p < 0.001), alanine aminotransferase (p = 0.035) and thyroid-stimulating hormone values (p = 0.013) than those with normal growth. Significantly associated with growth failure at diagnosis were age <3 years (OR 4.3 (95 % CI 2.5-7.5) vs older age), diagnosis before the year 2000 and in 2000–09 (OR 3.1 (1.8-5.4) and OR 1.8 (1.1-2.8) vs diagnosis in 2010–2013), presence of total and subtotal villous atrophy (OR 4.2 (2.5-7.0) and OR 2.0 (1.3-3.2) vs partial atrophy), severe symptoms (OR 3.4 (1.8-6.7) vs mild symptoms) and vomiting (OR 3.1 (1.5-6.3). The presence of abdominal pain reduced the risk (OR 0.5 (0.3-0.7)), while there was no effect of gender, diarrhea, constipation, other chronic diseases and celiac disease in the family. Children evincing poor growth as the sole clinical presentation were older (p < 0.001) and had higher hemoglobin (P < 0.001) and total iron (p = 0.010) values and lower TG2ab values (p = 0.009) than those with growth disturbance and other symptoms.

Conclusions

In particular young age and severe clinical and histological presentation were associated with growth disturbance at celiac disease diagnosis. Children with only poor growth are markedly different from those with other concomitant symptoms, suggesting different pathogenic mechanisms.

Keywords

Celiac diseaseChildrenGrowth failure

Background

Population-based screening studies have revealed celiac disease to be a very common health problem with a true prevalence of up to 3 % in children [1]. Besides the classical gastrointestinal symptoms, diarrhea and malabsorption, the condition may present with various extraintestinal manifestations [2]. A frequent, and sometimes the only clinical presentation is impaired growth [3, 4]. Despite being a long-recognized sign of the disease the pathophysiology and factors accompanying growth failure in celiac disease remain somewhat obscure. Traditionally the poor growth has been attributed to severe histological damage leading to malabsorption of essential nutrients, but the actual evidence for this is scant [5]. Other proposed mechanisms are for example abnormalities in the growth hormone/insulin-like growth factor-1 axis [68] and increased prevalence of anti-pituitary antibodies [9]. Regardless of the cause, after the commencement of a gluten-free diet significant catch-up growth usually follows [10]. However, in particular in those diagnosed in later childhood this may remain incomplete, leading possibly to reduced adult height [10], though this aspect remains controversial [11, 12]. The heterogeneous clinical picture of celiac disease makes it difficult to recognize and predisposes to long diagnostic delay [13], further increasing the risk of permanent growth failure. In order to prevent this complication it would be important to better understand the factors associated with poor growth in celiac disease.

In Finland celiac disease is common, and there have been nationwide guidelines for its diagnosis and treatment since the end of the 1990s [14]. A major aim of the regularly updated guidelines is early diagnosis and subsequent prevention of the possible severe complications, including poor growth in childhood. We here investigated the prevalence and associated factors in growth disturbance in pediatric celiac disease in the era of the modern diagnostic approach.

Methods

Patients and data collection

The study was conducted at the Tampere Center for Child Health Research, University of Tampere and Tampere University Hospital. The study cohort comprised 530 children (age under 16 years at diagnosis) with biopsy-proven celiac disease collected in our regularly updated pediatric research database. The patient information was either updated prospectively or collected from the medical records and, if incomplete, later supplemented with personal or parents’ interviews by a study nurse with expertise in celiac disease. The following information was gathered from all study subjects: demographic and anthropometric data, year of the celiac disease diagnosis, clinical presentation at diagnosis, values of serum celiac disease-specific antibodies and various laboratory parameters, severity of small-bowel mucosal damage and presence of either known celiac disease-associated or other concomitant chronic disease (e.g. type 1 diabetes mellitus, autoimmune thyroidal disease, asthma, allergies) and celiac disease in the family. After the analyses the children were divided into subjects with poor growth and those with normal growth prior to the celiac disease diagnosis (see below in detail).

Clinical symptoms

The severity of the clinical presentation at celiac disease diagnosis was further classified into four categories as follows: no symptoms (asymptomatic screen-detected subjects), mild symptoms (occasionally disturbing gastrointestinal or extraintestinal symptoms), moderate symptoms (multiple or more disturbing or frequent symptoms) and severe symptoms (symptoms seriously disturbing normal life; e.g. continuous symptoms or night awakenings due to the symptoms). Gastrointestinal symptoms were sub-categorized into diarrhea, abdominal pain, constipation and vomiting.

Serology and laboratory parameters

In our hospital the serum transglutaminase 2 (TG2ab) antibodies are measured using automatized human recombinant-based EliA assay (Phadia AB, Uppsala, Sweden). A TG2ab value of 7 U/l or higher is considered positive and the maximum reported value is 120 U/l. Serum endomysial antibodies (EmA) are measured in our research center by an indirect immunofluorescence-based in-house method using human umbilical cord as substrate [15]. An EmA dilution of 1:≥5 is considered positive and positive sera are further diluted from 1:50 to 1:4000.

The following laboratory values were collected from each child at diagnosis when available: blood hemoglobin (g/l), serum total iron (μmol/l), the mean corpuscular volume (MCV) (fl), serum alkaline phosphatase (U/l), serum alanine aminotransferase (ALT) (U/l), serum albumin (g/l), serum thyroid-stimulating hormone (TSH) (mU/l) and serum thyroxin (pmol/l). Anemia at diagnosis was defined as a blood hemoglobin value lower than that of the age- and gender-specific reference in the local hospital laboratory.

Small-bowel mucosal morphology

In our clinical practice a minimum of four duodenal samples are taken upon upper gastrointestinal endoscopy in all cases of celiac disease suspicion. The biopsies are passed to the pathology unit, where they are processed and analyzed. Only correctly oriented specimens are accepted for further microscopic analyses [16]. The severity of small-bowel mucosal villous atrophy here was categorized based on the hospital pathologist’s original grading into partial (PVA), subtotal (SVA) and total villous atrophy (TVA). These correspond approximately to Marsh-Oberhuber grades IIIa, IIIb and IIIc.

Growth parameters

Height-for-age was expressed in standard deviation (SD) units, which compare the height of a child to the average height of Finnish children of the same age [17]. Poor growth was defined as an abnormal deceleration of growth development compared with age- and gender-specific reference values or growth below the of expected target height based on the mean of parental heights [18]. The expected growth rate was considered abnormally low if the current height differed from the expected more than −2.3 SD. If the parental heights were not known, the child’s height was allowed to differ a maximum of −2.7 SD from the age- and sex-based reference [17]. In most cases the presence of poor growth was defined by the physician referring the patient for further endoscopic investigations. The weight of the children was expressed as weight-for-height percentage, as age- and gender-matched SD units and as body mass index (BMI, kg/m2).

Ethical aspects

Collection of the medical records and patient interviews were approved by the Department of Pediatrics, Tampere University Hospital and by the Ethics Committee of the Pirkanmaa Hospital District, Tampere, Finland. Written informed consent was obtained from all patients and/or their parents participating in the personal interviews.

Statistical analysis

Statistical analyses were performed using Statistical Package for the Social Sciences (SPSS) statistical software (SPSS Inc., Chicago, IL, USA). In Tables 1 and 4 the data are expressed either in medians with upper and lower quartiles (Q1, Q3) or as percentages and differences between the growth failure and normal growth groups were compared with Mann–Whitney U test or Chi square test. In Tables 2 and 3 the relative risk of growth failure is expressed using odds ratios with 95 % confidence intervals. A P value < 0.05 was considered statistically significant.
Table 1

Baseline characteristics in 530 children with or without growth failure before celiac disease diagnosis

  

Growth failure n = 182

 

Normal growth n = 348

 
 

n a

Median (Q1, Q3)

n a

Median (Q1, Q3)

P value

Age at diagnosis, yr

182

6.3 (2.5, 11.7)

348

8.0 (5.0, 12.0)

<0.001

Age of menarche, yr

23

13.0 (12.0, 13.0)

45

12.0 (12.0, 13.0)

0.146

Height, SDb

45

−0.5 (−1.2, 0.4)

134

0.2 (−0.5, 0.9)

0.004

Weight, SD

34

−1.1 (−1.9, −0.2)

114

−0.3 (−0.9, 0.6)

0.003

Weight/height percentage

65

−9.0 (−15.0, −1.0)

163

0.1 (−8.0, 9.0)

<0.001

Body mass index, kg/m2

68

15.7 (14.3, 16.6)

155

16.6 (15.1, 19.2)

<0.001

EmA, titer

81

500 (200, 2000)

205

200 (100, 1000)

<0.001

TG2ab, U/lc

98

120.0 (71.3, 120.0)

253

120.0 (39.0, 120.0)

0.035

Hemoglobin, g/l

129

122 (115, 128)

248

126 (115, 133)

0.016

MCV, fl

96

81 (75, 83)

207

81 (76, 83)

0.662

Alkaline phosphatase, U/l

42

309 (148, 511)

79

231 (184, 322)

0.180

ALT, U/l

34

24 (18, 32)

83

20 (16, 25)

0.035

Total iron, μmol/l

33

10.0 (6.6, 15.0)

58

12.5 (9.3, 17.8)

0.304

Albumin, g/l

18

37 (34, 41)

50

39 (37, 41)

0.252

TSH, mU/l

43

2.8 (2.2, 3.7)

58

2.4 (1.6, 3.1)

0.013

Thyroxin, pmol/l

31

14.4 (12.6, 16.9)

25

14.8 (12.9, 16.3)

0.817

Q1, Q3, lower and upper quartiles; SD, standard deviation; EmA, endomysial antibodies; TG2ab, transglutaminase 2 antibodies; MCV, mean corpuscular volume; ALT, alanine aminotransferase; TSH, thyroid stimulating hormone

aData available

bIncludes only measurements made by a pediatrician at the time of gastrointestinal endoscopy

cUpper limit of the assay 120.0 U/l

Table 2

Association between clinical characteristics and growth disturbance at diagnosis in 530 children with celiac disease

 

n a

Growth failure, %

Odds ratio

95 % CI

P value

Gender

     

 Boys

194

33.5

1

  

 Girls

336

34.8

1.06

0.73 - 1.54

0.759

Age at diagnosis, years

     

 <3

74

66.2

4.32

2.49 - 7.48

<0.001

 3-7

203

26.6

0.80

0.53 - 1.20

0.281

 8-17

253

31.2

1

  

Year of diagnosis

     

 <2000

114

48.2

3.11

1.82 - 5.35

<0.001

 2000-09

277

34.3

1.75

1.10 - 2.78

0.019

 2010-13

139

23.0

1

  

Type 1 diabetes mellitus

     

 No

475

33.7

1

  

 Yes

41

24.4

0.64

0.30 - 1.33

0.228

Thyroid disease

     

 No

502

32

1

  

 Yes

13

54

2.45

0.81 - 7.40

0.113

 No

474

32.9

1

  

 Yes

42

33.3

1.02

0.52 - 1.99

0.956

History of allergy

     

 No

393

34.9

1

  

 Yes

125

28.0

0.73

0.47 - 1.13

0.157

Other concomitant chronic diseaseb

     

 No

202

29.7

1

  

 Yes

315

35.6

1.31

0.89 - 1.91

0.169

First-degree relative with celiac disease

     

 No

157

35.7

1

  

 Yes

140

26.4

0.65

0.39 - 1.07

0.087

aData available

bE.g. epilepsy, rheumatoid arthritis, psychiatric disorder, inflammatory bowel disease, congenital heart disease, immune deficiency

Table 3

Association between histologic and symptomatic presentation and growth disturbance

 

n a

Growth failure, %

Odds ratio

95 % CI

P value

Degree of small-bowel mucosal villous atrophy

 Partial

174

20.7

1

  

 Subtotal

194

34.5

2.02

1.26 - 3.24

0.003

 Total

126

52.4

4.22

2.54 - 7.00

<0.001

Severity of symptomsb

 Mild

258

28.7

1

  

 Moderate

107

35.5

1.37

0.85 - 2.21

0.198

 Severe

43

58.1

3.45

1.78 - 6.70

<0.001

Asymptomatic

121

37.2

1.47

0.93 - 2.33

0.097

 Diarrhea

 No

319

32.3

1

  

 Yes

181

37.6

1.26

0.86 - 1.85

0.232

Abdominal pain

 No

267

42.7

1

  

 Yes

230

25.7

0.46

0.32 - 0.68

<0.001

Constipation

 No

425

35.8

1

  

 Yes

72

26.4

0.64

0.37 - 1.13

0.124

Vomiting

 No

466

32.4

1

  

 Yes

32

59.4

3.05

1.47 - 6.34

0.003

Anemia

     

 No

420

32.4

1

  

 Yes

91

37.4

1.25

0.78 - 2.00

0.361

aData available

bGrowth failure was not considered as a symptom here at diagnosis in 530 children with celiac disease

Table 4

Comparison of baseline data between celiac children with poor growth as sole clinical presentation and those with other concomitant symptoms

 

n a

Poor growth as only symptom n = 46

n a

Poor growth with other symptoms n = 136

P value

Age at dg, median, yr

46

11.5 (7.4, 13.1)

136

5.0 (2.0, 10.0)

<0.001

Girls, %

46

54

136

67

0.104

Anemia, %

40

15

130

22

0.085

Degree of villous atrophy, %

0.449

 Partial

10

23

26

21

 

 Subtotal

14

32

53

42

 

 Total

20

45

46

37

 

Body mass index, kg/m2

24

15.5 (14.3, 17.0)

44

15.8 (14.3, 16.5)

0.847

Hemoglobin, g/l

28

128 (123, 135)

101

120 (110, 127)

<0.001

MCV, fl

23

82 (78, 85)

73

79 (74, 83)

0.039

Alkaline phosphatase

10

284 (119, 640)

32

320 (148, 511)

0.859

Total iron, μmol/l

8

19.5 (9.9, 34.2)

25

7.5 (5.6, 14.2)

0.010

TSH, mU/l

12

3.1 (1.8, 3.8)

31

2.7 (2.0, 3.6)

0.684

Thyroxin, pmol/l

8

15.9 (14.3, 18.1)

23

14.2 (12.5, 16.4)

0.298

EmA, titer

26

500 (200, 1250)

81

1000 (200, 4000)

0.516

TG2ab, U/l

31

120 (30, 120)

67

120 (95, 120)

0.009

aData available

SD, standard deviation; MCV, mean corpuscular volume; TSH, thyroid stimulating hormone; EmA, endomysial antibodies; TG2ab, transglutaminase 2 antibodies

Results

Altogether 182 (34 %) children presented with disturbed growth and 348 (66 %) with normal growth at celiac diagnosis. Children with poor growth were significantly younger and had by definition lower median height but also lower weight parameters compared with those with normal growth (Table 1). There was also a trend towards later onset of menarche in girls with growth failure, but this was not significant (Table 1).

Serum EmA and TG2ab values were significantly higher in the growth failure group than in the normal growth group at diagnosis (Table 1). Further, median hemoglobin was significantly lower and ALT and TSH higher in children with poor growth. TSH was above the reference in 4 children with growth disturbance and in 2 with normal growth; however, none of these 6 had TSH values >10 mU/l or other clinical signs of hypothyroidism such as fatigue, increasing weight or weakness. No differences in thyroxin values or other laboratory parameters were observed between the groups (Table 1). Previously diagnosed concomitant thyroid disease under treatment was noted in 7 (4.1 %) children with poor growth and 6 (1.7 %) with normal growth (p = 0.102).

Among the demographic and clinical characteristics significantly associated with growth disturbance at celiac disease diagnosis was age below three years compared with older age and celiac disease diagnosis before the year 2010 compared with the later era (Table 2). There was no association between growth failure and gender, presence of any other concomitant chronic disease or presence of celiac disease in the family (Table 2).

A significant association was seen between abnormal growth and the presence of subtotal and total small-bowel mucosal villous atrophy (Table 3). Of symptoms overall the presence of in general severe symptoms and of specific gastrointestinal symptoms vomiting increased the risk of poor growth. In contrast, abdominal pain reduced the risk, whereas the presence of diarrhea, constipation and anemia had no effect (Table 3).

In a separate analysis among the 182 children with growth failure this was the sole clinical presentation of celiac disease in 46 (25 %) subjects at diagnosis, while the remaining 136 (75 %) also had other clinical symptoms (Table 4). Children with poor growth as the sole manifestation were significantly older and had higher hemoglobin, MCV and total iron values and lower TG2ab values than those with other concomitant symptoms, while there were no significant differences between the groups in the other study variables (Table 4).

Discussion

The present study demonstrated that children with poor growth at celiac disease diagnosis are significantly younger and have more severe disease in terms of symptoms, serology and histological damage compared with those with normal growth. It was also shown that the risk of growth failure has decreased during the past few decades, and that children with growth failure as the sole presentation are markedly different from those with concomitant other symptoms.

The association between histology and growth was demonstrated by the more frequent observation of poor growth in children with subtotal or total villous atrophy compared with those with partial atrophy. Although a seemingly logical finding, there is a surprising scarcity of studies touching upon this issue, and the few conducted have shown no clear relationship [19, 21, 22]. This discrepancy between the present and earlier results might be explained by the smaller numbers of patients in previous studies and variable definitions of growth failure. Weizman and colleagues [19] also speculated that the extent of mucosal damage might be more related to poor growth in celiac disease than the degree of atrophy; this is however, contradicted by evidence that the extent of enteropathy does correlate with clinical presentation [22]. Our findings support the role of villous atrophy and malabsorption of essential nutrients as an important cause of decreased growth in celiac disease. In accord with this was the observation of lower weight and hemoglobin values in the growth failure group. Similarly, even though still mostly at normal level, the ALT values were significantly higher level in children with poor growth, again indicating more advanced disease.

Here children with poor growth had significantly higher celiac antibody levels at diagnosis than those with normal growth. Previously Bingley and colleagues [23] have shown EmA-positive children to be shorter and lighter than corresponding seronegative non-celiac children. To our knowledge, however, the difference in serology noted here in children with celiac disease has not been reported before. The finding is in accord with the previously shown association between higher antibody levels and more severe histological and clinical presentation [20, 24, 25]. The correlation between serology and poor growth might thus in fact be a result of more severe mucosal damage, but it is also possible that the antibodies have a direct role in the disease pathogenesis [26].

The presence of growth failure was also associated with generally more severe gastrointestinal symptoms. Of specific symptoms vomiting increased the risk, while diarrhea, somewhat unexpectedly, did not. In contrast, the presence of the “non-classical” symptom abdominal pain in fact reduced the risk. Severity of gastrointestinal symptoms has previously been linked with more advanced villous atrophy in some studies [19, 24] but not in others [27, 28]. Interestingly, adult celiac disease patients with diarrhea were recently shown to have less severe villous atrophy than those with anemia [29]. Although in that study the possible confounding diseases such as microscopic colitis were not systemically excluded, it nicely demonstrates the complicated relationship between clinical and histological presentation in celiac disease. It is also possible to have growth-disturbing protein-losing enteropathy without diarrhea [30]. The protective effect of abdominal pain might be explained for example by less severe villous atrophy in these subjects. Obviously more studies are needed to decipher the mechanisms behind the multifaceted clinical picture in celiac disease.

Children with poor growth were almost two years younger than those with normal growth, and at particular risk were those below three years at diagnosis. Similar results have previously been reported from Sweden [31]. These findings suggest that the rapid growth during infancy is particularly vulnerable to malabsorption caused by untreated celiac disease. Conversely, it is possible that toddlers with poor growth as a presenting symptom are diagnosed earlier since they are regularly followed in child welfare clinics. Interestingly, children with growth failure as the sole presentation were significantly older than those with concomitant other symptoms. There could be different pathophysiological mechanisms present, and it has indeed been speculated that poor growth in children with classical symptoms is caused by malabsorption and in those with atypical presentation by abnormalities in the growth hormone-insulin-like growth factor axis [68, 32]. Also, as presumed in Crohn’s disease [33, 34], mucosal inflammation may directly contribute to abnormal growth. Because of the increased risk of growth hormone deficiency, there should be low threshold for endocrinological evaluation in children with no significant catch-up growth after one year on a gluten-free diet.

Interestingly, the TSH values here were higher in the growth failure group. Children with celiac disease are known to be at increased risk of autoimmune thyroid diseases [34]. This notwithstanding, only four children with growth failure had TSH values above the reference and none of them had other hypothyreosis symptoms or values usually required for such a diagnosis [35]. It is still possible that subclinical hypothyreosis had an exacerbating effect on the poor growth, but currently it remains controversial whether these children would benefit from hormone replacement therapy [36]. In any case, it is important to remember the possibility of associated thyroid disease in poorly growing children with celiac disease.

The finding that risk of growth failure was decreased over time is in line with other recent reports [4, 31, 37] and very likely reflects earlier diagnosis due to increased awareness and improved diagnostic tools. We found a higher prevalence of poor growth than previously reported by Savilahti and colleagues [4] but lower than that reported by group under Rashid [38]. These discrepancies might be explained by differences in definition, as growth failure has often been defined as a height below −2 SD compared with the reference population (“short stature”) [4], whereas we defined it as either height below the expected target or abnormal deflection of the growth. The latter method has proved effective and may allow indentification children with celiac disease earlier and thus reduce the risk of permanent growth failure [19, 39]. In contrast, short stature as such is often only a normal variant and thus not a particularly reliable marker for true growth abnormality [40].

The strengths of this study were its large size and well-defined celiac disease diagnoses. We also had a wide range of clinically relevant data on each patient. Nevertheless, in particular laboratory values were lacking in a substantial part of the study subjects. Another limitation was that, although proved appropriate, the definition of growth failure used here might limit generalization of the results. Finally, since growth hormone metabolism or other endocrinological factors possibly implicated were not investigated here, we cannot verify the mechanisms underlying poor growth, this being an issue for future studies.

Conclusions

To conclude, our results demonstrate that growth failure in symptomatic children with celiac disease is associated in particular with young age and severe presentation at diagnosis. Differences between children having poor growth as the sole clinical presentation and those with concomitant other symptoms indicate that there are different underlying mechanisms.

Declarations

Acknowledgements

This study was supported by the Academy of Finland Research Council for Health, the Competitive State Research Financing of the Expert Responsibility Areas of Tampere University Hospital (Grants 9P060, 9R018, 9R034), the Sigrid Juselius Foundation, the Mary and Georg Ehrnrooth Foundation, the Foundation for Pediatric Research, and the Finnish Medical Foundation. The funding body had no role in design, in the collection, analysis and interpretation of data, in the writing of the manuscript, or in the decision to submit the manuscript for publication.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
School of Medicine, University of Tampere
(2)
Tampere Center for Child Health Research, University of Tampere and Tampere University Hospital
(3)
School of Health Sciences, University of Tampere
(4)
Department of Internal Medicine, Tampere University Hospital

References

  1. Myleus A, Ivarsson A, Webb C, Danielsson L, Hernell O, Högberg L, et al. Celiac disease revealed in 3 % of Swedish 12-year-olds born during an epidemic. J Pediatr Gastroenterol Nutr. 2009;49:170–6.View ArticlePubMedGoogle Scholar
  2. Hernandez L, Green PH. Extraintestinal manifestations of celiac disease. Curr Gastroenterol Rep. 2006;8:383–9.View ArticlePubMedGoogle Scholar
  3. Bottaro G, Cataldo F, Rotolo N, Spina M, Corazza GR. The clinical pattern of subclinical/silent celiac disease: an analysis on 1026 consecutive cases. Am J Gastroenterol. 1999;94:691–6.PubMedGoogle Scholar
  4. Savilahti E, Kolho KL, Westerholm-Ormio M, Verkasalo M. Clinics of coeliac disease in children in the 2000s. Acta Paediatr. 2010;99:1026–30.View ArticlePubMedGoogle Scholar
  5. Holtmeier W, Caspary W. Celiac disease. Orphanet J Rare Dis. 2006;1:3.View ArticlePubMedPubMed CentralGoogle Scholar
  6. Jansson UH, Kristiansson B, Magnusson P, Larsson L, Albertsson-Wikland K, Bjarnason R. The decrease of IGF-I, IGF-binding protein-3 and bone alkaline phosphatase isoforms during gluten challenge correlates with small intestinal inflammation in children with coeliac disease. Eur J Endocrinol. 2001;144:417–23.View ArticlePubMedGoogle Scholar
  7. Street ME, Volta C, Ziveri MA, Zanacca C, Banchini G, Viani I, et al. Changes and relationships of IGFS and IGFBPS and cytokines in coeliac disease at diagnosis and on gluten-free diet. Clin Endocrinol. 2008;68:22–8.View ArticleGoogle Scholar
  8. Ferrante E, Giavoli C, Elli L, Redaelli A, Novati E, De Bellis A, et al. Evaluation of GH-IGF-I axis in adult patients with coeliac disease. Horm Metab Res. 2010;42:45–9.View ArticlePubMedGoogle Scholar
  9. Delvecchio M, De Bellis A, Francavilla R, Rutigliano V, Predieri B, Indrio F, et al. Anti-pituitary antibodies in children with newly diagnosed celiac disease: a novel finding contributing to linear-growth impairment. Am J Gastroenterol. 2010;105:691–6.Google Scholar
  10. Patwari AK, Kapur G, Satyanarayana L, Anand VK, Jain A, Gangil A, et al. Catch-up growth in children with late-diagnosed coeliac disease. Br J Nutr. 2005;94:437–42.View ArticlePubMedGoogle Scholar
  11. Weiss B, Skourikhin Y, Modan-Moses D, Broide E, Fradkin A, Bujanover Y. Is adult height of patients with celiac disease influenced by delayed diagnosis? Am J Gastroenterol. 2008;103:1770–4.View ArticlePubMedGoogle Scholar
  12. Pärnänen A, Kaukinen K, Helakorpi S, Uutela A, Lähdeaho ML, Huhtala H, et al. Symptom-detected and screen-detected celiac disease and adult height: a large cohort study. Eur J Gastroenterol Hepatol. 2012;24:1066–70.View ArticlePubMedGoogle Scholar
  13. Fuchs V, Kurppa K, Huhtala H, Collin P, Mäki M, Kaukinen K. Factors associated with long diagnostic delay in celiac disease. Scand J Gastroenterol. 2014;49:1304–10.PubMedGoogle Scholar
  14. Coeliac disease (online). Current Care Guidelines. Working group set up by the Finnish Medical Society Duodecim and the Finnish Society of Gastroenterology. Helsinki: The Finnish Medical Society Duodecim, 2010. Available online at: www.kaypahoito.fi. Accessed 20 October 2014.
  15. Ladinser B, Rossipal E, Pittschieler K. Endomysium antibodies in coeliac disease: an improved method. Gut. 1994;35:776–8.View ArticlePubMedPubMed CentralGoogle Scholar
  16. Taavela J, Koskinen O, Huhtala H, et al. Validation of morphometric analyses of small-intestinal biopsy readouts in celiac disease. PLoS One. 2013;8, e76163.View ArticlePubMedPubMed CentralGoogle Scholar
  17. Saari A, Sankilampi U, Hannila ML, Kiviniemi V, Kesseli K, Dunkel L. New Finnish growth references for children and adolescents aged 0 to 20 years: Length/height-for-age, weight-for-length/height, and body mass index-for-age. Ann Med. 2011;43:235–48.View ArticlePubMedGoogle Scholar
  18. Saari A, Harju S, Mäkitie O, Saha MT, Dunkel L, Sankilampi U. Systematic growth monitoring for the early detection of celiac disease in children. JAMA Pediatr. 2015;169, e1525.View ArticlePubMedGoogle Scholar
  19. Weizman Z, Ben-Zion YZ, Binsztok M, Maor E, Porath A. Correlation of clinical characteristics and small bowel histopathology in celiac disease. J Pediatr Gastroenterol Nutr. 1997;24:555–8.View ArticlePubMedGoogle Scholar
  20. Donaldson MR, Firth SD, Wimpee H, Leiferman KM, Zone JJ, Horsley W, et al. Correlation of duodenal histology with tissue transglutaminase and endomysial antibody levels in pediatric celiac disease. Clin Gastroenterol Hepatol. 2007;5:567–73.View ArticlePubMedGoogle Scholar
  21. Jatla M, Bokhari A, Bierly P, Russo P, Verma R. Anthropometric, serologic, and laboratory correlation with villous blunting in pediatric celiac disease: diabetics are different. J Clin Gastroenterol. 2009;43:622–6.View ArticlePubMedGoogle Scholar
  22. Murray JA, Rubio-Tapia A, Van Dyke CT, Brogan DL, Knipschield MA, Lahr B, et al. Mucosal atrophy in celiac disease: extent of involvement, correlation with clinical presentation, and response to treatment. Clin Gastroenterol Hepatol. 2008;6:186–93.View ArticlePubMedGoogle Scholar
  23. Bingley PJ, Williams AJ, Norcross AJ, Unsworth DJ, Lock RJ, Ness AR, et al. Undiagnosed celiac disease at age seven: population based prospective birth cohort study. BMJ. 2004;328:322–3.View ArticlePubMedPubMed CentralGoogle Scholar
  24. Taavela J, Kurppa K, Collin P, Lähdeaho ML, Salmi T, Saavalainen P, et al. Degree of damage to the small bowel and serum antibody titers correlate with clinical presentation of patients with celiac disease. Clin Gastroenterol Hepatol. 2013;11:166–71.View ArticlePubMedGoogle Scholar
  25. Agardh D, Lee HS, Kurppa K, et al. for the TEDDY Study Group. Clinical Features of Celiac Disease: A Prospective Birth Cohort. Pediatrics. 2015;135:627–34.View ArticlePubMedPubMed CentralGoogle Scholar
  26. Lindfors K, Kaukinen K. Contribution of celiac disease autoantibodies to the disease process. Expert Rev Clin Immunol. 2012;8:151–4.View ArticlePubMedGoogle Scholar
  27. Brar P, Kwon GY, Egbuna II, Holleran S, Ramakrishnan R, Bhagat G, et al. Lack of correlation of degree of villous atrophy with severity of clinical presentation of coeliac disease. Dig Liver Dis. 2007;39:26–9.View ArticlePubMedGoogle Scholar
  28. Thomas HJ, Ahmad T, Rajaguru C, Barnardo M, Warren BF, Jewell DP. Contribution of histological, serological, and genetic factors to the clinical heterogeneity of adult-onset coeliac disease. Scand J Gastroenterol. 2009;44:1076–83.View ArticlePubMedGoogle Scholar
  29. Abu Daya H, Lebwohl B, Lewis SK, Green PH. Celiac disease patients presenting with anemia have more severe disease than those presenting with diarrhea. Clin Gastroenterol Hepatol. 2013;11:1472–7.View ArticlePubMedGoogle Scholar
  30. Umar SB, DiBaise JK. Protein-losing enteropathy: case illustrations and clinical review. Am J Gastroenterol. 2010;105:43–9.View ArticlePubMedGoogle Scholar
  31. Ludvigsson JF, Ansved P, Fälth-Magnusson K, Hammersjö JA, Johansson C, Edvardsson S, et al. Symptoms and signs have changed in Swedish children with coeliac disease. J Pediatr Gastroenterol Nutr. 2004;38:181–6.View ArticlePubMedGoogle Scholar
  32. Catassi C, Fasano A. Celiac disease as a cause of growth retardation in childhood. Curr Opin Pediatr. 2004;16:445–9.View ArticlePubMedGoogle Scholar
  33. Sanderson IR. Growth problems in children with IBD. Nat Rev Gastroenterol Hepatol. 2014;11:601–10.PubMedGoogle Scholar
  34. Elfström P, Montgomery SM, Kämpe O, Ekbom A, Ludvigsson JF. Risk of thyroid disease in individuals with celiac disease. J Clin Endocrinol Metab. 2008;93:3915–21.View ArticlePubMedGoogle Scholar
  35. Pearce SH, Brabant G, Duntas LH, Monzani F, Peeters RP, Razvi S, et al. 2013 ETA Guideline: Management of Subclinical Hypothyroidism. Eur Thyroid J. 2013;2:215–28.View ArticlePubMedPubMed CentralGoogle Scholar
  36. Bona G, Prodam F, Monzani A. Subclinical hypothyroidism in children: natural history and when to treat. J Clin Res Pediatr Endocrinol. 2013;5(S1):23–8.PubMedPubMed CentralGoogle Scholar
  37. Roma E, Panayiotou J, Karantana H, Constantinidou C, Siakavellas SI, Krini M, et al. Changing pattern in the clinical presentation of pediatric celiac disease: a 30-year study. Digestion. 2009;80:185–91.View ArticlePubMedGoogle Scholar
  38. Rashid M, Cranney A, Zarkadas M, Graham ID, Switzer C, Case S, et al. Celiac disease: evaluation of the diagnosis and dietary compliance in Canadian children. Pediatrics. 2005;116:754–9.View ArticleGoogle Scholar
  39. Oostdijk W, Grote F, de Muinck K-SS, Wit J. Diagnostic approach in children with short stature. Horm Res. 2009;72:206–17.View ArticlePubMedGoogle Scholar
  40. Cohen LE. Idiopathic short stature: a clinical review. JAMA. 2014;311:1787–96.View ArticlePubMedGoogle Scholar

Copyright

© Nurminen et al. 2015

Advertisement